Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics (Nasdaq: ARQT) reported the grant of 94,500 restricted stock units to 12 newly hired employees as inducement awards under the 2022 Inducement Plan.
The awards were approved by the Compensation Committee, granted with a grant date of October 1, 2025, and disclosed on October 3, 2025 in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years, with 25% vesting on each annual anniversary, contingent on continuous employment through each vesting date.
Arcutis Biotherapeutics (Nasdaq: ARQT) ha annunciato l'assegnazione di 94.500 unità di azioni restritte a 12 dipendenti recentemente assunti come premi di induzione ai sensi del Piano di Induzione 2022.
Le premi sono stati approvati dal Compensation Committee, concessi con una data di attribuzione del 1 ottobre 2025, e resi noti il 3 ottobre 2025 in conformità con la Nasdaq Listing Rule 5635(c)(4). Le RSU maturano in quattro anni, con il 25% che matura a ogni anniversario annuale, soggette a un impiego continuativo fino a ciascuna data di vesting.
Arcutis Biotherapeutics (Nasdaq: ARQT) anunció la concesión de 94.500 unidades de stock restringido a 12 empleados recién contratados como premios de inducción bajo el Plan de Inducción 2022.
Los premios fueron aprobados por el Comité de Compensación, otorgados con una fecha de otorgamiento del 1 de octubre de 2025, y divulgados el 3 de octubre de 2025 de acuerdo con la Regla de Listado de Nasdaq 5635(c)(4). Las RSUs se consolidan a lo largo de cuatro años, con un 25% que vence en cada aniversario anual, sujeto a empleo continuo hasta cada fecha de vesting.
Arcutis Biotherapeutics(나스닥: ARQT)는 12명의 신규 채용 직원에게 94,500개의 제한 주식 단위를 유인 보상으로 부여했다고 발표했습니다. 이는 2022년 유인 계획에 따른 것입니다.
보상은 보상위원회가 승인했고 부여일 2025년 10월 1일에 부여되었으며 나스닥 상장 규칙 5635(c)(4)에 따라 2025년 10월 3일에 공시되었습니다. RSUs는 4년에 걸쳐 가속 vesting되며, 매년 기념일에 25%가 vesting되고 각 vesting 날짜까지 지속적으로 고용되어야 합니다.
Arcutis Biotherapeutics (Nasdaq: ARQT) a annoncé l'octroi de 94 500 units d'actions restreintes à 12 nouveaux salariés dans le cadre des plans d'induction 2022.
Les attributions ont été approuvées par le Comité de rémunération, accordées avec une date d'octroi du 1er octobre 2025, et divulguées le 3 octobre 2025 conformément à la Règle de cotation Nasdaq 5635(c)(4). Les RSU se libèrent sur quatre ans, avec 25% qui se libèrent à chaque anniversaire annuel, sous réserve d'un emploi continu jusqu'à chaque date de vesting.
Arcutis Biotherapeutics (Nasdaq: ARQT) gab 99.500 eingeschränkte Aktieneinheiten an 12 neu eingestellte Mitarbeiter als Anreizpreise gemäß dem 2022 Inducement Plan bekannt.
Die Zuteilungen wurden vom Vergütungsausschuss genehmigt, mit einem Zuteilungsdatum vom 1. Oktober 2025 gewössen und am 3. Oktober 2025 entsprechend der Nasdaq Listing Rule 5635(c)(4) offengelegt. Die RSUs vesten über vier Jahre, mit 25% Vesting an jedem jährlichen Jahrestag, vorausgesetzt, die Anstellung bleibt bis zu jedem Vesting-Datum bestehen.
Arcutis Biotherapeutics (ناسداك: ARQT) أعلنت عن منح 94,500 وحدة أسهم مقيدة لـ 12 موظفاً جديداً كجوائز حافزة وفقاً لـ خطة الإ诱诱 2022.
تمت الموافقة على الجوائز من قبل اللجنة المعنية بالتعويض، ومنحت بتاريخ 1 أكتوبر 2025، وكُشِف عنها في 3 أكتوبر 2025 وفقاً لـ قاعدة إدراج ناسداك 5635(c)(4). تتقادم RSUs خلال أربعة أعوام، مع 25% تكتسب مع كل ذكرى سنوية، رهن الاستمرار في العمل حتى تاريخ التقادم.
Arcutis Biotherapeutics（纳斯达克股票代码：ARQT） 公布向 12名新雇员授予的94,500份受限股票单位，作为 2022年诱导计划下的诱导性奖励。
这些奖励经薪酬委员会批准，授予日期为2025年10月1日，并于2025年10月3日根据纳斯达克上市规则5635(c)(4)披露。RSU在四年内归属，每年纪念日归属25%，前提是每个归属日之前持续在职。
- None.
- None.
WESTLAKE VILLAGE, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 94,500 restricted stock units of Arcutis’ common stock to 12 newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of October 1, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25 percent vesting on each annual anniversary of the vesting commencement date, subject to the employee being continuously employed by Arcutis as of such vesting dates.
Arcutis is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis’ unique dermatology development platform coupled with our dermatology expertise allows us to invent differentiated therapies against biologically validated targets, and has produced a robust pipeline for a range of inflammatory dermatological conditions. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations and are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2025, as well as any subsequent filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com
Investors
Brian Schoelkopf, Head of Investor Relations
ir@arcutis.com
FAQ
What did Arcutis (ARQT) announce on October 3, 2025 about inducement grants?
How do the Arcutis (ARQT) RSUs vest and when did they grant them?
Why did Arcutis (ARQT) use Nasdaq Listing Rule 5635(c)(4) for these grants?
How many employees received inducement awards from Arcutis (ARQT)?
Do the Arcutis (ARQT) press release details imply immediate dilution to shareholders?
Who approved the Arcutis (ARQT) inducement awards?
